Next Article in Journal
Thermal Boundaries in Cone Calorimetry Testing
Previous Article in Journal
The Synthesis of a Superhydrophobic and Thermal Stable Silica Coating via Sol-Gel Process
Previous Article in Special Issue
High Intensity Laser Induced Reverse Transfer: Solution for Enhancement of Biocompatibility of Transparent Biomaterials
Open AccessReview

Benefits of Nanomedicine for Therapeutic Intervention in Malignant Diseases

1
Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, Craiova 710204, Romania
2
Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, Craiova 710204, Romania
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this study.
Coatings 2019, 9(10), 628; https://doi.org/10.3390/coatings9100628
Received: 29 August 2019 / Revised: 24 September 2019 / Accepted: 26 September 2019 / Published: 29 September 2019
Cancer remains one of the most difficult to manage healthcare problems. The last two decades have been considered the golden age of cancer research, with major breakthroughs being announced on a regular basis. However, the major problem regarding cancer treatment is the incapability to selectively target cancer cells, with certain populations of tumors still remaining alive after treatment. The main focus of researchers is to develop treatments that are both effective and selective in targeting malignant cells. In this regard, bioavailability can be increased by overcoming the biological barriers encountered in the active agent’s pathway, creating carrier vehicles that have the ability to target malignant cells and effectively release the active agent. Since its appearance, nanomedicine has provided many answers to these challenges, but still, some expectations were not satisfied. In this review, we focused on the most recent developments in targeted drug delivery. Furthermore, a summary of different types of nanoparticles used to deliver active therapeutic agents in oncology is presented, along with details on the nanodrugs that were clinically approved by the Food and Drug Administration (FDA), until April 2019. View Full-Text
Keywords: cancer therapy; nanoparticles; targeted delivery cancer therapy; nanoparticles; targeted delivery
Show Figures

Graphical abstract

MDPI and ACS Style

Sevastre, A.-S.; Horescu, C.; Carina Baloi, S.; Cioc, C.E.; Vatu, B.I.; Tuta, C.; Artene, S.A.; Danciulescu, M.M.; Tudorache, S.; Dricu, A. Benefits of Nanomedicine for Therapeutic Intervention in Malignant Diseases. Coatings 2019, 9, 628.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop